Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Home
Submit a press release Sign up now! Categories Entertainment Blog Refer this site HelloArticle
Get the latest news
with our RSS feed
More information
Business
Peregrine Pharmaceuticals, Inc. (PPHM) - Financial and Strategic Analysis Review
Peregrine Pharmaceuticals, Inc. (PPHM) - Financial and Strategic Analysis Review - new company profile and swot report published
Print article
Refer to a friend
© companiesandmarkets.com
companiesandmarkets.com
2010-06-15 16:03:01 - Peregrine Pharmaceuticals, Inc. (PPHM) - Financial and Strategic Analysis Review - a new market research report on companiesandmarkets.com
Peregrine Pharmaceuticals, Inc. (PPHM) - Financial and Strategic Analysis Review
Peregrine Pharmaceuticals, Inc. (Peregrine) is a publicly held pharmaceutical company. It is engaged in the development and manufacture of monoclonal antibodies for the treatment of cancer and serious viral infections.
Peregrine Pharmaceuticals, Inc. Key Recent Developments
Apr 21, 2010: Peregrine Announces Three Data Presentations Of Phospholipid-Targeting Technologies At AACR
Apr 12, 2010: Peregrine Launches
Investigator-Sponsored Trial Program
Apr 05, 2010: Peregrine Reports Data From Newly Published Research Reinforcing Potential Of Targeting PS In HIV Infection
Mar 16, 2010: Avid Bioservices Presents Data Of Single-Use Bioreactor Systems
Jan 11, 2010: Peregrine Names Marvin Garovoy As Head Of Clinical Science
This comprehensive SWOT profile of Peregrine Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company?s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company?s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of the ?Profile on Demand? service, covering over 50,000 of the world?s leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Peregrine Pharmaceuticals, Inc., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).
The profile contains critical company information including*,
- Business description ? A detailed description of the company?s operations and business divisions.
- Corporate strategy ? Analyst?s summarization of the company?s business strategy.
- SWOT Analysis ? A detailed analysis of the company?s strengths, weakness, opportunities and threats.
- Company history ? Progression of key events associated with the company.
- Major products and services ? A list of major products, services and brands of the company.
- Key competitors ? A list of key competitors to the company.
- Key employees ? A list of the key executives of the company.
- Executive biographies ? A brief summary of the executives? employment history.
- Key operational heads ? A list of personnel heading key departments/functions.
- Important locations and subsidiaries ? A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities ? A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years ? The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods ? The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company?s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors? business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company?s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies? strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Click for report details: www.companiesandmarkets.com/Summary-Company-Profile/peregrine-ph ..(pphm)-financial-and-strategic-analysis-review-292265.asp?prk=8949ddb9f9365145ccac710ea4fbba60
Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600
Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Terms & Conditions | Privacy | About us | Contact PR-inside.com
When I get ready to sell all my shares,please remind me to have Wm. Smith & Co. sell them for me. I'm sure they will get top dollar for them.
I stand corrected an even later trade up 3 cents. God is good.
The MM'S running this stock are a bunch of Sadistic B--tards.
They trade 100 share lots all day to keep Peregrine from any kind of a move, just look at the last trade 499 shares and they knock it down 2 cents.
CJ appreciate the answer
What price will PPHM need to get into the Russell?
To Big World and PPHMTOLONG
Look into Univ of Penn. Hospital in Philadelphia for GBM treatment with Cotara.
I was waiting for the mention of the DUKE PAPER
Strange they never brought it up, I guess that was just another Scam.
They kept their perfect record. Never has the PPS gone up on the day of a CC
On the eve of our Dec. CC just keep in mind PPHM has never gone up on a CC day.
I was going to hold my vote till the day before the SHM, I have
changed my mind. My 265,000 shares are going against the boards recommendation. To me it looks like a move to .50 cents
a share, a reverse 1 for 10 and then the pipes will start all over again and we will see prices well below the 5.00 dollar
range. Shareholders are going to be screwed again. This BOD is only looking out for themselves and continued paychecks.If they have enough votes for their options fine. What good will they be if the share price keeps falling?
vol. I say they did the same with PPHM. I hate to say it cause I own a bunch of PPHM but if the big boys do what I think they are going to do, we will never see a huge move.
Vol Whats your point. 2007 was 2 years ago
We all had a lesson in how to take over a company.
Mederex closed at 8.40 today and will open at 15.95 tomorrow.
How many shares of Mederex did BMS own before they made that announcement? No one knows but the big shots at BMS.Is there any doubt that a big company interested in taking over PPHM
already has locked up a large block of stock. I'm sure they own it at very low prices so they don't care if they have to stretch for the rest of it.
Just saw this any ideas what is so confidential
Document
Base
UNITED STATES
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
July 20, 2009
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Peregrine Pharmaceuticals, Inc.
File No. 1-32839 - CF#23319
_____________________
Peregrine Pharmaceuticals, Inc. submitted an application under Rule 24b-2
requesting confidential treatment for information it excluded from the Exhibits to a Form
10-Q filed on March 12, 2009.
Based on representations by Peregrine Pharmaceuticals, Inc. that this information
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the following
exhibit(s) will not be released to the public for the time period(s) specified:
Exhibit 10.111 through March 12, 2012
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Christian Windsor
Special Counsel
To all longs
Just remember there has never been an up day on a cc day.
Prepare to be disappointed.
When I was in my teens and not working yet I didn't have a great deal of money. When my brother celebrated a birthday I always gave him 20.00 and on my birthday he gave me 20.00.I think the same thing is hapening with PPHM. MM sells 100 shares his partner sells him 100 shares and they do this all day back and forth.They are stifling the market. I give up I'm just going to wait for news and see if they won't give up and let this seek a legitimate level.
This is a great deal of info that will be updated now that the law suit has been settled
http://www.jco.org/cgi/content/full/23/7/1538
I think everyone is missing the DIOS revenues. 50 million
dollar contract signed over a year ago. That money is just flowing in.If it isn't then I think we are owed an explanation.
How can a company make that bold a statement and not deliver.
I for one would like to sue the company for false information
I made a large purchase of stock after hearing that and I have llost a bundle and feel I should be re embursed
Last night on ABC news they reported that Avistan and Erbitux
combination treatment for colon cancer was harmful. Full story will be in NEJM today
If this is a pre news move why don't we all have the news? If news moved us today I say they have inside friend alerted before the rest of us. Foul! Shame on Management
They want to hire a person to handle new contracts, why not put Mary Boyd in charge, She hasn't done anything since they hired her. She must be tired of running, put her at a desk and let her pay for her keep.
if who ever is in charge of keeping the pps down stops and goes the other way they can make this baby fly
They gave RR rep a lot of time. That is all a set up. He had a script.
248,500 votes no
I came across this earlier today, has any one else seen this?
Cardiovascular | Oncology | Pain & Inflammation | Central Nervous System | Infectious Disease
Article Preview
SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
From the PharmaLive.com News Archive - Aug. 07, 2008
DUBLIN, Calif., August 07, 2008 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer.
The FDA accepted SuperGen's application upon review of data from in vitro studies in glioblastoma cell lines that demonstrate that either MP-470 or ionizing radiation (IR) alone induce cell death, but when used in combination they ...
To continue reading the complete article, login or register
below and get free instant access.
In an Oncology report I received this morning, Avantis is now going to be used with docetaxil{sic}I guess they know it works better.
Also todays weakness in PPHM smells I think someone has leaked some info that might be harmful in the short term.
In reading this P/R I see no mention of the DIOS contract.
When Mgt. released this news last year I think it was all hype and there was never a DIOS deal.
Handle every stressful situation like a dog....
.... Piss on it and walk away.
Realists
Go back to 1993 and you will see LOMK had a reverse split 1 for 15. I know I owned it I bought 80k at 30 cents and wound up with 5300 shares. After the R/S I had 5333 shares.I may be off by a year one way or the other but it happened that I guarantee.It traded at 3.75 a share and the rest is history.
lomk Lomak Petroleum R/S and now it's RRC
The R'S came on a 1-15 was at .39 cents then opened at 3.75
now trading at 65.00
This is an opportunity for the next pipe. All the selling is just prep for the pipe
ricardo beat us both
l Therapeutics: Immunotherapy
Meeting: 2008 ASCO Annual Meeting
Abstract No: 3038
Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 3038)
Author(s): R. Digumarti, P. P. Bapsy, J. S. Shan
Abstract: Background: Bavituximab (B) is a first in class anti-phosphatidylserine (PS) monoclonal antibody. This immunotherapeutic agent selectively binds to PS exposed on tumor blood vessels causing an enhanced immune response and shutting down blood flow into the tumor. Pre-clinical data suggest a synergistic action using anti-PS antibodies in combination with chemotherapy. Methods: This was an open-label, non- randomized, multi-center study in pts with refractory advanced solid tumors. B was given weekly for up to 8 weeks, at a dose of 3mg/kg i.v., in combination with docetaxel (D)(75-80mg/m2 every 3 weeks) or gemcitabine (G) (1,000mg/m2 weeks 1-7) or paclitaxel (175mg/m2 every 3 weeks) plus carboplatin (AUC=5) (P+C). Study objectives were to assess safety and tolerability of B and to characterize its PK profile when used in combination with chemotherapeutic agents. Serum levels of B were determined by ELISA. Results: 14 pts were enrolled, mean age was 48.4yr, 78.6% were female. All had a stage IV tumor. 5 pts received B+D, 5 pts received B+G and 4 pts received B+P+C. Pts received a mean of 6 doses of B. AEs were reported by 13 pts. Most common were vomiting (6pts), cough (4 pts), asthenia, pain, headache, neutropenia, prolonged aPTT and pain in extremities, each in 3pts. 3 pts reported SAEs considered to be related to B, 1 pt had non-related SAE. On Days 0 and 21, no significant differences in PK characteristics were seen between the three treatment groups following administration of B. No accumulation of B was seen following multiple dose administration. Using RECIST criteria, week 8 tumor responses were PR (3pts), SD (3pts) and PD (6pts); 2 pts were non-evaluable. Conclusions: The PK of B was not impacted by co-administration of conventional chemotherapy. 50% of all evaluable pts achieved an objective tumor response or stable disease. These findings warrant further efficacy studies of B in pts with refractory solid tumors. Bavituximab Pharmacokinetics Day 0 (Dose 1) Day 21 (Dose 4)
Treatment Arm Cmax
System Tumors
Category: Central Nervous System Tumors
Meeting: 2008 ASCO Annual Meeting
Abstract No: 2072
Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 2072)
Author(s): S. Shen, R. Lustig, K. D. Judy, J. B. Fiveash, J. S. Shan
Abstract: Background: 131I-chTNT-1/B MAb (Cotara [C]) is a radioiodinated chimeric monoclonal antibody specific for DNA and histone H1 complex, which becomes exposed in the necrotic areas of gliomas. This is the first report on biodistribution and dosimetry of C for treatment of recurrent glioma. In a prior phase I trial with a single catheter, C was infused over ~25 hrs using convection enhanced delivery (CED). This current trial assesses the use of 2 interstitial catheters to deliver C via CED. Methods: Patients with recurrent GBM and tumor volume of 5-60 cc are eligible. Patients receive 3 mCi of C for imaging and dosimetry followed 2-4 weeks later with a therapy dose. Cohorts of 3-6 patients will be enrolled to receive a therapy dose of 1.5, 2.0 or 2.5 mCi/cc. Biodistribution and dosimetry of C is determined using 5 sequential whole body images and counting 9 blood samples. Uptake and clearance of C in tissues were quantified and radiation doses were determined based on Medical Internal Radiation Dose schema. Results: Three patients received an imaging dose and then a therapy dose at 1.5 mCi/cc, both infused over ~25 hrs with 2 interstitial catheters. The administered therapeutic radiation dose ranged from 17- 74 mCi and no dose limiting toxicities (DLT) were observed. From images acquired immediately and up to 168 hours post infusion, Cotara was concentrated only in tumor. Minimal uptake of Cotara could be faintly visualized only in stomach, heart, and thyroid. The peak uptake ranged from 1.1-3.3 %ID for stomach, 0.4-1.2 %ID for heart, 0.05-0.26 %ID for thyroid, 0.0009-0.0017 %ID/mL for blood, and 30-55.7 %ID for tumor. Radiation doses ranged 1.8-3.3 cGy/mCi for stomach, 0.9-1.6 cGy/mCi for heart, 0.7-4.4 cGy/mCi for thyroid, 0.9-1.6 cGy/mCi for contralateral healthy brain, 0.64-1.1 cGy/mCi for marrow from radioactivity in blood, and 179-598 cGy/mCi for tumor. Mean tumor-to-body dose ratio was 551 and ranged 223-732. Conclusions: CED administered C specifically localized only in tumor with minimal systemic radiation exposure. No DLTs were observed at the 1.5 mCi/cc dose level. These clinical and biodistribution/dosimetry findings are encouraging and support further dose escalation.
Thanks Pharmboy
Over a year ago Peregrine anounced a deal with DIOS that would be worth 50 million. The stock price ran and then was knocked down at the bell. What ever happened to this deal? Was that a lie by management? I think they should be held accountable. If anyone bought on that news they should be able to sue if that info was false.
Reakists
I didn't ask you to butt in.
EZ gave me my answer and I understand it as for you I got wise remarks. You know where you can put your wise remarks.